FDA
-
-
-
-
-
-
-
BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX)
-
-
-
-
-
-
-
Needham: 'we believe that IMDX is making good progress towards its GraftAssureDx submissions'
-
-
-
-
-
-
-
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
-
-
-
-
-
-
-
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
-
-
-
-
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

